Fig. 2

(a) ITT

- Carboplatin: 59 of 188 (31.4%)
- Docetaxel: 64 of 188 (34.0%)

Absolute difference
-2.6% (95% CI, -12.1 to 6.9)
Exact P = 0.86

(b) Germine BRCA1/2 mutation

- Mutated BRCA:
  - 17 of 25 (68.0%)
  - Absolute difference: 34.7% (95% CI, 6.3 to 63.1)
  - Exact P = 0.03

- Wild-type BRCA:
  - 36 of 128 (28.1%)
  - Absolute difference: -6.4% (95% CI, -17.4 to 4.6)
  - Exact P = 0.30

Interaction test P = 0.01

(c) Tumor BRCA1/2 mutation

- Mutated BRCA:
  - 12 of 18 (66.7%)
  - Absolute difference: 31.0% (95% CI, -2.2 to 64.2)
  - Exact P = 0.15

- Wild-type BRCA:
  - 23 of 90 (25.6%)
  - Absolute difference: -10.0% (95% CI, -23.4 to 3.4)
  - Exact P = 0.20

Interaction test P = 0.03

(d) BRCA1 methylation

- Methylation:
  - 3 of 14 (21.4%)
  - Absolute difference: -20.7% (95% CI, -51.6 to 10.2)
  - Exact P = 0.28

- Normal:
  - 32 of 93 (34.8%)
  - Absolute difference: -4.0% (95% CI, -18.1 to 10.1)
  - Exact P = 0.64

Interaction test P = 0.35

(e) BRCA1 mRNA level

- BRCA1 mRNA-low:
  - 4 of 14 (28.6%)
  - Absolute difference: -36.1% (95% CI, -68.9 to 3.3)
  - Exact P = 0.07

- Not BRCA1 mRNA-low:
  - 24 of 78 (30.8%)
  - Absolute difference: 0.9% (95% CI, -12.3 to 15.3)
  - Exact P = 1.00

Interaction test P = 0.07

Key: Carboblatin | Docetaxel | 95% CI
Fig. 3

a) ITT

b) Germline BRCA1/2 mutation

- Mutated BRCA1/2: 2.6 months (0.11 to 5.12) P = 0.04
- Wild-type BRCA1/2: 0.97 months (-1.05 to -0.09) P = 0.03

n at risk (events)
- Carboplatin 186 (12) 97 (40) 57 (35) 22 (8) 14 0
- Docetaxel 186 (58) 129 (62) 67 (46) 19 (11) 8 0

Months from randomization
- Carboplatin
- Docetaxel

n at risk (events)
- C = BRCA1/2-wt 128 (65) 64 (29) 35 (24) 11 (5) 6 0
- C = BRCA1/2-mut 25 (4) 21 (6) 15 (8) 7 (1) 6 0
- D = BRCA1/2-wt 145 (39) 106 (50) 56 (39) 17 (10) 7 1
- D = BRCA1/2-mut 15 (7) 10 (3) 7 (7) 1 (0) 1 0

Months from randomization
- C = BRCA1/2-wt 90 (48) 42 (21) 21 (13) 8 (5) 3 0
- C = BRCA1/2-mut 10 (6) 3 (1) 1 (0) 0 0
- D = BRCA1/2-wt 90 (27) 63 (37) 26 (22) 4 (4) 1 0
- D = BRCA1/2-mut 10 (5) 6 (3) 4 (4) 0 0

Tumor BRCA1/2 mutation

- Mutated BRCA1/2: 1.55 months (-1.43 to 4.56) P = 0.30
- Wild-type BRCA1/2: -0.30 months (-1.13 to 0.53) P = 0.47

n at risk (events)
- C = BRCA1/2-mut 10 (6) 3 (1) 1 (0) 0 0
- D = BRCA1/2-mut 10 (5) 6 (3) 4 (4) 0 0

Months from randomization
- C = BRCA1/2-wt 90 (27) 63 (37) 26 (22) 4 (4) 1 0
- D = BRCA1/2-wt 90 (27) 63 (37) 26 (22) 4 (4) 1 0

BRCA1 methylation

- Methylated: -0.31 months (-0.93 to 0.31) P = 0.71
- Nonmethylated: 0.01 months (-0.89 to 0.98) P = 0.99

n at risk (events)
- C = Methylated 93 (45) 48 (18) 30 (20) 10 (4) 6 0
- C = Nonmethylated 14 (8) 6 (4) 2 (2) 1 (0) 0 0
- D = Methylated 86 (56) 60 (33) 27 (22) 5 (3) 2 0
- D = Nonmethylated 19 (5) 14 (9) 8 (8) 0 (0) 0 0

BRCA1 mRNA level

- mRNA-low: -1.12 months (-3.10 to 0.87) P = 0.26
- Not mRNA-low: 0.10 months (-0.67 to 1.07) P = 0.84

n at risk (events)
- C = mRNA-low 82 (42) 40 (17) 23 (15) 8 (3) 5 0
- C = Not mRNA-low 14 (9) 6 (3) 3 (1) 2 (0) 0 0
- D = mRNA-low 70 (27) 51 (30) 21 (17) 4 (2) 2 0
- D = Not mRNA-low 17 (5) 15 (8) 7 (7) 1 (0) 0 0
a

Dichotomized HRD score

HRD high

13 of 34 (38.2%)

19 of 47 (40.4%)

Absolute difference

-2.2% (95% CI, -23.7 to 19.3)

Exact P = 1.00

HRD low

20 of 65 (30.8%)

14 of 49 (28.6%)

Absolute difference

2.2% (95% CI, -14.7 to 19.1)

Exact P = 0.84

Interaction test P = 0.75

b

HR deficiency status

HR deficient

17 of 38 (44.7%)

19 of 48 (39.6%)

Absolute difference

5.1% (95% CI, -15.9 to 26.1)

Exact P = 0.67

Not HR deficient

17 of 62 (27.4%)

14 of 48 (29.2%)

Absolute difference

-1.8% (95% CI, -18.8 to 15.2)

Exact P = 1.00

Interaction test P = 0.63

Key

Carboplatin

Docetaxel

95% CI
**Fig. 5**

### a. Basal-like PAM50

<table>
<thead>
<tr>
<th>Group</th>
<th>Count</th>
<th>Percentage</th>
<th>Absolute Difference</th>
<th>95% CI</th>
<th>Exact P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal-like</td>
<td>27</td>
<td>32.5%</td>
<td>1.5%</td>
<td>-12.5 to 15.5</td>
<td>0.87</td>
</tr>
<tr>
<td>Not basal-like</td>
<td>13</td>
<td>72.2%</td>
<td>-55.5%</td>
<td>-85.3 to -25.7</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Interaction test $P = 0.003$

### b. Core basal IHC

<table>
<thead>
<tr>
<th>Group</th>
<th>Count</th>
<th>Percentage</th>
<th>Absolute Difference</th>
<th>95% CI</th>
<th>Exact P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core basal</td>
<td>23</td>
<td>34.3%</td>
<td>5.1%</td>
<td>-10.8 to 21.0</td>
<td>0.58</td>
</tr>
<tr>
<td>5NP</td>
<td>13</td>
<td>41.9%</td>
<td>-22.7%</td>
<td>-45.7 to 0.3</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Interaction test $P = 0.06$

**Key**
- orange: Carboplatin
- green: Docetaxel
- line: 95% CI
Fig. 6

a

**Basal-like PAM50**

- Basal: 0.22 months (-0.69 to 1.13)
- Nonbasal: -2.07 months (-4.01 to -0.14)

<table>
<thead>
<tr>
<th>组别</th>
<th>n</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>C + Nonbasal</td>
<td>18</td>
<td>9 (5)</td>
<td>4 (2)</td>
<td>2 (2)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>C + Basal</td>
<td>83</td>
<td>39 (15)</td>
<td>24 (16)</td>
<td>8 (3)</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>D + Nonbasal</td>
<td>18</td>
<td>16 (5)</td>
<td>11 (8)</td>
<td>3 (3)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>D + Basal</td>
<td>87</td>
<td>58 (38)</td>
<td>20 (18)</td>
<td>2 (2)</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

b

**Core basal IHC**

- Core basal: 0.49 months (-0.60 to 1.58)
- 5NP: -1.02 months (-2.71 to 0.68)

<table>
<thead>
<tr>
<th>组别</th>
<th>n</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>C + 5NP</td>
<td>26</td>
<td>11 (6)</td>
<td>5 (2)</td>
<td>3 (3)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>C + Core basal</td>
<td>67</td>
<td>35 (12)</td>
<td>23 (15)</td>
<td>8 (3)</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>D + 5NP</td>
<td>31</td>
<td>23 (10)</td>
<td>13 (10)</td>
<td>3 (3)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>D + Core basal</td>
<td>65</td>
<td>44 (27)</td>
<td>17 (15)</td>
<td>2 (2)</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>